Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
20 07 2022
Historique:
pubmed: 1 4 2022
medline: 20 7 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival and to compare MTV with the International Prognostic Index (IPI) and its individual components to derive the best prognostic model. PET scans and clinical data were included from five published studies in newly diagnosed diffuse large B-cell lymphoma. Transformations of MTV were compared with the primary end points of 3-year progression-free survival (PFS) and overall survival (OS) to derive the best relationship for further analyses. MTV was compared with IPI categories and individual components to derive the best model. Patients were grouped into three groups for survival analysis using Kaplan-Meier analysis; 10% at highest risk, 30% intermediate risk, and 60% lowest risk, corresponding with expected clinical outcome. Validation of the best model was performed using four studies as a test set and the fifth study for validation and repeated five times. The best relationship for MTV and survival was a linear spline model with one knot located at the median MTV value of 307.9 cm A new prognostic index is proposed using MTV, age, and stage, which outperforms IPI and enables individualized estimates of patient outcome.

Identifiants

pubmed: 35357901
doi: 10.1200/JCO.21.02063
pmc: PMC9287279
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2352-2360

Subventions

Organisme : Department of Health
ID : RP-2-16-07-001
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT203148/Z/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom

Références

Stat Med. 2013 Aug 15;32(18):3158-80
pubmed: 23307585
J Nucl Med. 2020 Jan;61(1):40-45
pubmed: 31201248
J Clin Oncol. 2015 Aug 10;33(23):2523-9
pubmed: 26150440
Br J Haematol. 2021 Feb;192(3):504-513
pubmed: 32621535
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1142-1154
pubmed: 29460024
Leuk Lymphoma. 2015;56(9):2556-62
pubmed: 25629994
J Nucl Med. 2018 Apr;59(4):589-595
pubmed: 28864629
J Nucl Med. 2021 Mar;62(3):332-337
pubmed: 32680929
Radiology. 2019 Feb;290(2):488-495
pubmed: 30511907
J Clin Oncol. 2020 Oct 10;38(29):3377-3387
pubmed: 32730183
Stat Med. 2006 Jan 15;25(1):127-41
pubmed: 16217841
Blood. 2020 Apr 16;135(16):1396-1405
pubmed: 31978225
Ann Oncol. 2016 Apr;27(4):719-24
pubmed: 26787236
Blood. 2018 Mar 29;131(13):1456-1463
pubmed: 29437590
Ann Hematol. 2012 May;91(5):697-703
pubmed: 22071570
Eur J Cancer. 2020 Jan;124:25-36
pubmed: 31710995
Blood. 2015 Jan 1;125(1):22-32
pubmed: 25499448
Blood. 2014 Feb 6;123(6):837-42
pubmed: 24264230
J Clin Oncol. 2005 Aug 1;23(22):5027-33
pubmed: 15955905
Leuk Lymphoma. 2015;56(9):2487-8
pubmed: 25721755
Blood. 2017 May 11;129(19):2616-2623
pubmed: 28251914
J Nucl Med. 2019 Aug;60(8):1096-1102
pubmed: 30954945
J Clin Oncol. 2018 Jul 10;36(20):2024-2034
pubmed: 29750632
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood Adv. 2021 May 11;5(9):2375-2384
pubmed: 33944897
Blood. 2020 Jun 4;135(23):2041-2048
pubmed: 32232482
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19
pubmed: 26902371
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):932-942
pubmed: 34405277
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
Blood Adv. 2020 Mar 24;4(6):1082-1092
pubmed: 32196557
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877

Auteurs

N George Mikhaeel (NG)

Department of Clinical Oncology, Guy's Cancer Centre and School of Cancer and Pharmaceutical Sciences, King's College London University, London, United Kingdom.

Martijn W Heymans (MW)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.

Jakoba J Eertink (JJ)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Henrica C W de Vet (HCW)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.

Ronald Boellaard (R)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Ulrich Dührsen (U)

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Luca Ceriani (L)

Department of Oncology, IOSI-Oncology Institute of Southern Switzerland, Bellinzona; Università della Svizzera Italiana, Bellinzona, Switzerland.
SAKK-Swiss Group for Clinical Cancer Research, Bern, Switzerland.

Christine Schmitz (C)

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Sanne E Wiegers (SE)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Andreas Hüttmann (A)

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Pieternella J Lugtenburg (PJ)

Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.

Emanuele Zucca (E)

Department of Oncology, IOSI-Oncology Institute of Southern Switzerland, Bellinzona; Università della Svizzera Italiana, Bellinzona, Switzerland.
SAKK-Swiss Group for Clinical Cancer Research, Bern, Switzerland.

Gerben J C Zwezerijnen (GJC)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Otto S Hoekstra (OS)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Josée M Zijlstra (JM)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Sally F Barrington (SF)

King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's Health Partners, Kings College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH